Bea Fertility is a technology company.
Bea Fertility has raised $5.0M across 2 funding rounds.
Bea Fertility has raised $5.0M in total across 2 funding rounds.
Bea Fertility has raised $5.0M in total across 2 funding rounds.
Bea Fertility's investors include Calm/Storm Ventures, Frontline Ventures, QVentures.
Béa Fertility is a femtech company providing at-home fertility treatments, specializing in a hormone-free intracervical insemination (ICI) kit that delivers clinic-level care between natural conception and IVF.[1][3][5] It serves couples and individuals facing early infertility challenges, solving the gap in accessible, affordable options by offering a 3-cycle program with 39.28% pregnancy rates—outperforming first-cycle IVF (20-35%)—at under 1/10th the cost, paired with virtual clinical support, diagnostics, and lifestyle guidance.[1][3][5] Formerly StepOne Fertility, founded in 2020 and based in London, the company has raised $4.32M (£3M), achieved FDA Class 2 clearance in 2025, delivered 2,700 treatment cycles, supported 1,250 patients, and reported 29+ live births as of mid-2024, with expansion into the US.[1][2][4]
Béa Fertility was founded in 2020 by Tess Cosad, a clinician-driven entrepreneur motivated by personal experiences and the frustrations of friends navigating fertility delays, high costs, and the "try naturally for 12 months" gap before IVF access.[1][2] The idea emerged from recognizing ICI's efficacy—tested since the 1970s but sidelined by pricier clinic procedures like IUI and IVF—and reimagining it for at-home use with modern data, remote care, and social shifts in fertility openness.[2][3] After pitching to Angel Academe in 2020 (initial £2.25M valuation), it secured seed funding from Calm/Storm Ventures, Forward Partners, JamJar Investments, Octopus Ventures, QVentures, and 7percent Ventures, achieving 8.4x MOIC and £19M valuation.[2][3][4] Key milestones include 2 years of R&D with 90 prototypes (2021-2023), UK launch in 2023, 39.28% pregnancy rate in a single-arm study and NPS 90 in 2024, and US entry with FDA clearance plus 2,700 cycles in 2025.[1]
Béa rides the femtech boom, targeting the underserved $75B primary fertility market (25M US users) amid rising social acceptance, remote healthcare adoption, and demand for consumer-led solutions between timed intercourse and invasive IVF/IUI.[2][3] Timing aligns with post-pandemic telehealth normalization, data-driven personalization, and fertility awareness via apps/trackers, reviving ICI from the 1970s by leveraging at-home tech to disrupt clinic monopolies on high-margin procedures.[3] Market forces like IVF inaccessibility (only 3% eligible get it) and aging parenthood trends favor Béa, influencing the ecosystem by proving femtech's clinical-commercial viability—drawing VC interest (Octopus, JamJar) and paving the way for scalable, equitable reprotech beyond tabs like Flo or Mira.[2][3][4]
Béa Fertility is poised to scale US dominance post-FDA clearance, expanding its 3-cycle model with more diagnostics, global kits, and partnerships at GPs/OBGYNS to capture primary care share.[1][3][5] Trends like AI-optimized fertility tracking, microbiome innovations (e.g., Freya Biosciences), and policy pushes for affordable reprotech will amplify growth, potentially hitting 10x cycles amid femtech's maturation.[2][3][4] Its influence may evolve from UK pioneer to global standard-setter, rewriting fertility pathways and delivering parenthood control to millions—bridging that critical gap from day one.[1]
Bea Fertility has raised $5.0M across 2 funding rounds. Most recently, it raised $4.0M Venture Round in July 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2023 | $4.0M Venture Round | Calm/Storm Ventures, Frontline Ventures, QVentures | |
| Mar 1, 2021 | $1.0M Seed | Calm/Storm Ventures, Frontline Ventures, QVentures |